Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 8—August 2006

Research

Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†Comments to Author 
Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Table 2

Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia patients by CD4+ count and week of observation*

Week All patients
CD4+ <50 cells/μL
CD4+ >50 cells/μL
n Geometric mean (95% CI) n Geometric mean (95% CI) n Geometric mean (95% CI)
Baseline (0) 80 4.2 (3.1–5.8) 54 4.2 (2.8–6.3) 26 4.4 (2.5–7.6)
1–2 25 8.0 (4.1–15.8) 17 7.3 (3.0–17.8) 8 9.9 (2.8–35.3)
3–4 19 10.4 (4.7–23.1)† 13 6.3 (2.4–16.4) 6 30.4 (7.1–129.5)‡
5–6 18 3.7 (2.0–6.8) 10 5.5 (2.0–15.0) 8 2.3 (1.2–4.4)

*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 vs. week 0, p<0.001 vs. weeks 1–2, and p<0.001 vs. weeks 5–6.
‡p<0.001 vs. week 0, p<0.001 vs. weeks 5–6, p<0.03 vs. weeks 3–4 in CD4+ <50 cells/μL group.

Main Article

TOP